Study guide

14.3 Specimen Handling and Shipping (IATA/dangerous goods)

Certified Clinical Research Coordinator CCRC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Scientific Concepts and Research Design

1.1 Protocol Elements 1.2 Study Design and Objectives 1.3 Study Endpoints and Biostatistics

2 Chapter 2: Ethical Principles and Guidelines

2.1 Ethical Principles (Declaration of Helsinki, Belmont Report) 2.2 Informed Consent Process and Documentation 2.3 Vulnerable Populations and Assent

3 Chapter 3: IRB/IEC Oversight and Participant Safety

3.1 IRB/IEC Functions and Oversight 3.2 Adverse Event Classification and Reporting 3.3 Safety Monitoring and Safety Reporting

4 Chapter 4: Participant Rights and Ethics

4.1 Participant Rights and Confidentiality (HIPAA/GDPR) 4.2 Conflicts of Interest 4.3 Ethical Scenarios in Clinical Trials

5 Chapter 5: Product Development and Regulatory Framework

5.1 Drug and Device Development Phases 5.2 U.S. and International Regulatory Frameworks 5.3 Investigational Product Investigator's Brochure (IB)

6 Chapter 6: Investigational Product Accountability

6.1 Investigational Product Labeling and Storage 6.2 Investigational Product Receipt, Dispensing, and Accountability 6.3 Investigational Product Return and Destruction

7 Chapter 7: Regulatory Submissions and Actions

7.1 Regulatory Submissions (IND, NDA, IDE, PMA) 7.2 Regulatory Actions and Compliance 7.3 Pharmacokinetics and Pharmacodynamics in Product Development

8 Chapter 8: Clinical Trial Operations and GCP Principles

8.1 Introduction to ICH E6 GCP Principles (including R3 updates) 8.2 Investigator Responsibilities under GCP 8.3 Sponsor Responsibilities and Oversight

9 Chapter 9: Essential Documents and Site Qualification

9.1 Essential Documents (Pre-study, During, Post-study) 9.2 Site Selection and Qualification 9.3 Quality Management and Standard Operating Procedures (SOPs)

10 Chapter 10: Protocol Deviations and Amendments

10.1 Protocol Adherence and Compliance 10.2 Protocol Deviations and Violations 10.3 Protocol Amendments and Version Control

11 Chapter 11: Monitoring Visits and Audits

11.1 Monitoring Preparation and Visit Types 11.2 Monitoring Visits (SIV, IMV, COV) 11.3 Regulatory Inspections and Site Audits

12 Chapter 12: Study and Site Management - Startup

12.1 Site Startup Operations 12.2 Site Budget and Contract Management 12.3 Site Staffing, Training, and Documentation

13 Chapter 13: Enrollment and Recruitment

13.1 Enrollment Management and Strategies 13.2 Participant Recruitment and Retention 13.3 Participant Compensation and Ethics

14 Chapter 14: Daily Trial Coordination

14.1 Visit Scheduling and Logistics 14.2 Equipment Maintenance and Calibration 14.3 Specimen Handling and Shipping (IATA/dangerous goods)

15 Chapter 15: Quality Improvement and Site Closeout

15.1 Participant Safety Management 15.2 Quality Improvement and Site Audits Preparation 15.3 Study and Site Closeout Procedures

16 Chapter 16: Source Documentation and Case Report Forms

16.1 Source Documentation Standards (ALCOA-C) 16.2 Case Report Forms and eCRF Completion 16.3 Electronic Data Capture (EDC) Systems

17 Chapter 17: Data Management and Queries

17.1 Data Management Processes 17.2 Data Queries and Discrepancy Resolution 17.3 Data Correction and Audit Trails

18 Chapter 18: Data Privacy and Records Retention

18.1 Data Privacy and Confidentiality 18.2 Records Retention and Archiving 18.3 Compliance in Clinical Trial Informatics

14.3 Specimen Handling and Shipping (IATA/dangerous goods)

Key Takeaways Explain This Topic AI

IATA Dangerous Goods certification is mandatory for anyone packaging and shipping biological specimens and must be renewed every 24 months.

Clinical trial specimens typically fall under UN3373, Biological Substance, Category B, which requires strict triple packaging.

Pre-analytical errors during sample processing (e.g., incorrect clotting times, wrong centrifuge speed) frequently invalidate lab results.

Dry ice is a Miscellaneous Dangerous Good (UN1845) and must never be placed in a hermetically sealed package, to allow gas venting.

The laboratory requisition form serves as the primary Chain of Custody document and must accurately reflect collection and processing times.

Last updated: October 2026

IATA Certification and Dangerous Goods Regulations

Shipping biological specimens—such as blood, urine, tissue, and cerebrospinal fluid—is heavily regulated on an international level because these materials can pose significant infectious risks in transit. The International Air Transport Association (IATA) and the U.S. Department of Transportation (DOT) govern the transport of dangerous goods.

Mandatory Training Requirements

Any individual who packages, labels, or signs a declaration for dangerous goods must complete specialized IATA dangerous goods training. Crucially, this training must be renewed every 24 months (two years). A CRC without current IATA certification cannot legally package or ship biological specimens; doing so violates federal and international law and can result in severe fines for the research site.

Classification of Biological Specimens

Most routine clinical trial specimens fall under UN3373, Biological Substance, Category B . This classification applies to infectious substances that do not generally cause fatal or life-threatening disease in healthy humans or animals upon exposure. (In contrast, Category A includes highly fatal pathogens like Ebola).

The Triple Packaging System

IATA regulations mandate a strict triple packaging system to ensure Category B substances do not leak during turbulent flights or rough handling:

Primary Receptacle : A leak-proof tube, vial, or cup containing the biological specimen.

Secondary Packaging : A second leak-proof container enclosing the primary receptacle. It must contain sufficient absorbent material (like specialized absorbent pads) to soak up all liquid if the primary receptacle breaks.

Rigid Outer Packaging : A sturdy exterior box clearly labeled with the UN3373 diamond mark, the proper shipping name ("Biological Substance, Category B"), and the contact information of the responsible person.